New agents in the treatment of acute lymphocytic leukaemia

Deborah A. Thomas, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

The overall prognosis of adult patients with acute lymphocytic leukaemia (ALL) has improved significantly over the past few decades. Combined modality strategies (e.g. chemotherapy used with targeted therapies such as monoclonal antibodies or tyrosine kinase inhibitors) may improve long-term disease-free survival. Still, most patients succumb to complications of disease progression, with current long-term disease-free survival rates of 30-45% overall. Thus, either new strategies or refinements of old ones are needed to improve the long-term prognosis. An increasing number of unique active new chemotherapeutic and biological agents are available for study. This chapter reviews new agents with the potential to be incorporated into therapeutic strategies for the treatment of ALL.

Original languageEnglish (US)
Pages (from-to)771-790
Number of pages20
JournalBest Practice and Research: Clinical Haematology
Volume15
Issue number4
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Keywords

  • Acute lymphocytic leukaemia
  • Drug resistance
  • Novel agents

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'New agents in the treatment of acute lymphocytic leukaemia'. Together they form a unique fingerprint.

  • Cite this